Previous 10 | Next 10 |
2023-03-24 04:47:31 ET Summary Aurinia Pharmaceuticals' Lupkynis revenue figures aren't bad this quarter. However, the target population is the problem. I still think only a buyout from big pharma will unlock full potential. I covered Aurinia Pharmaceuticals ( ...
2023-03-24 00:53:15 ET Summary LUPKYNIS has had a lengthy and ultimately productive development pathway. Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch. Forward earnings prospects are challenged by Aurinia's meager pipeline and by significant compet...
2023-03-23 15:56:20 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 6.5% amid renewed takeover speculation. There's speculation than unnamed suitor may be eyeing a takeover of Aurinia ( AUPH ), according to a Betaville "uncooked" alert, which cited people followin...
2023-03-23 06:22:38 ET Summary Aurinia Pharmaceuticals Inc. has strengthened its patent position in the industry and now has more clout as a marketer than just a developer of therapies. Its lead product, LUPKYNIS, an immunosuppressive drug for lupus nephritis, appears to be a high...
2023-03-21 17:57:26 ET Summary Despite positive results from the AURA-LV study, Lupkynis has not become the preferred LN treatment, leading to Aurinia's missed 2022 revenue projections. A study indirectly comparing drug regimens for LN induction therapy indicates tacrolimus plus M...
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief...
Aurinia Pharmaceuticals ( NASDAQ: AUPH ) stock rose ~8% on Tuesday after Q4 net loss narrowed and revenue grew Y/Y. Net loss was -$26.05M, compared to -$33.32M in Q4 2021. Total net revenue grew +21.5% Y/Y to ~$28.44M, however it missed analysts estimates. Full year 2...
Aurinia Pharma press release ( NASDAQ: AUPH ): Q4 GAAP EPS of -$0.18 beats by $0.09 . Revenue of $28.4M (+21.4% Y/Y) misses by $0.42M . Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022. For fiscal year 2023, the Company is reiterati...
$28.4 million in total net revenue for the fourth quarter 2022, a 21% increase over fourth quarter 2021 and $134.0 million for full year 2022, a 194% increase over 2021 Cash, cash equivalents, and investments of $389.4 million as of December 31, 2022 Conference call to be hosted t...
Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q4 earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is -$0.27 (vs. -$0.25 last year) and the consensus Revenue Estimate is $28.82M (+23.2% Y/Y). Over the last 1 year, AUPH ...
News, Short Squeeze, Breakout and More Instantly...
Aurinia Pharmaceuticals Inc Company Name:
AUPH Stock Symbol:
NASDAQ Market:
Aurinia Pharmaceuticals Inc Website:
Viridien ADR (CGGYD) is expected to report for Q2 2024 Civitas Resources Inc. (CIVI) is expected to report $2.9 for Q2 2024 Aptiv PLC (APTV) is expected to report $1.37 for Q2 2024 Ardelyx Inc. (ARDX) is expected to report $-0.1 for Q2 2024 Beazer Homes USA Inc. (BZH) is expected ...
Company achieved $57.2 million in total net revenue and $55.0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Company generated approximately $15.8 million in free cash flow in the second quarter a...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the second quarter of 2024 on Thursday, August 1, 2024, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30...